Korro Bio, Inc. $KRRO Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its holdings in Korro Bio, Inc. (NASDAQ:KRRO) by 6,185.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 199,249 shares of the company’s stock after acquiring an additional 196,079 shares during the quarter. JPMorgan Chase & Co.’s holdings in Korro Bio were worth $9,542,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of KRRO. Geode Capital Management LLC boosted its position in shares of Korro Bio by 10.8% during the 2nd quarter. Geode Capital Management LLC now owns 155,387 shares of the company’s stock valued at $1,941,000 after purchasing an additional 15,166 shares in the last quarter. Raymond James Financial Inc. lifted its stake in Korro Bio by 357.6% during the second quarter. Raymond James Financial Inc. now owns 83,392 shares of the company’s stock valued at $1,042,000 after purchasing an additional 65,170 shares during the last quarter. Emerald Mutual Fund Advisers Trust bought a new stake in Korro Bio during the third quarter worth approximately $2,821,000. Bank of America Corp DE boosted its holdings in Korro Bio by 520.0% during the second quarter. Bank of America Corp DE now owns 28,156 shares of the company’s stock worth $352,000 after buying an additional 23,615 shares in the last quarter. Finally, Wealth Forward LLC acquired a new position in Korro Bio in the third quarter worth approximately $240,000. 13.18% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

KRRO has been the subject of a number of recent research reports. HC Wainwright reissued a “neutral” rating on shares of Korro Bio in a research note on Thursday, November 13th. Wall Street Zen downgraded Korro Bio from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Clear Str upgraded Korro Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 18th. JonesTrading cut Korro Bio from a “buy” rating to a “hold” rating in a research note on Friday, November 14th. Finally, Raymond James Financial set a $18.00 target price on Korro Bio in a report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $50.38.

Korro Bio Stock Up 2.1%

Korro Bio stock opened at $11.18 on Friday. Korro Bio, Inc. has a 12 month low of $5.20 and a 12 month high of $55.89. The stock has a market cap of $105.32 million, a P/E ratio of -1.19 and a beta of 2.98. The company’s fifty day simple moving average is $10.60 and its 200-day simple moving average is $20.45.

Korro Bio Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.